Ablexis delivers a transgenic mouse platform for the discovery of therapeutic antibodies.

Ablexis

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

HBM Holdings Limited

Ablexis, LLC | 499 followers on LinkedIn. A superior, next generation transgenic platform. | Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities.  The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties.

Ablexis, LLC

Thanks, Ian Wilkinson, for adding to the conversation about the importance of human Ig lambda light chains. I wholeheartedly agree about lambda light chains being important for engaging certain epitopes, either altogether or with sufficient affinity to meet potency requirements. I have 20+ years of accumulated anecdotal evidence, first using XenoMouse(R) Mice and now using AlivaMab(R) Mice.

From the 2014 generation 1 of AlivaMab Mouse to the generation 6 versions now being launched, we recognized the importance of including a well-functioning human Ig lambda light chain locus to maximize probability of success in antibody drug discovery. Our partners have benefited from that foresight. Talk to us to learn about the benefits of other unique design features incorporated into the AlivaMab Mouse strains that make them the best platform choice for antibody drug discovery.

Last year's Innovation Day was inspiring and a lot of fun. Meet us in San Diego at Innovation Day 2024 - it will be even better!

Jane always does a fantastic job in leading discussions and moderating panels. This will be a "can't miss" session!

Join the team at AlivaMab Biologics and help discover the next great biologic drug to improve patients' outcomes!

Don't miss this roundtable! Jane will do a great job in leading a scintillating discussion and debate.

Ablexis and AlivaMab Biologics celebrate our ten years of innovations in antibody drug discovery, commencing in 2014 with launch of the 1st generation AlivaMab® Mouse strains and continuing onward with our launching of the 6th generation AlivaMab Mouse strains, used in synergy with the innovative high-throughput discovery and engineering platforms of AlivaMab Biologics. The patented AlivaMab Mouse technology remains a platform differentiated from other transgenic animals and in vitro display technologies, providing superior performance and efficiency in antibody discovery while risk-mitigating downstream development. Our most recent innovations include the AlivaMab Mouse-XKL strains, demonstrated to produce even greater combinatorial diversity in the IgG repertoire, and AlivaMab Mouse-SD, for the discovery of single-domain human VH antibodies. For common light chain antibody discovery, AlivaMab Biologics offers its unique platform that combines the best of in vivo, in vitro, and NGS-based discovery. To learn more about why AlivaMab Mouse and AlivaMab Biologics provide the best platforms for biologics drug discovery and engineering, contact us at info@alivamab.com or info@ablexis.com .

Thank you to the many people with whom we met at East Coast Antibody HubXChange! Lots of follow-ups!

Another AlivaMab antibody achieves an important clinical milestone!

Come meet with us next week in Woburn, MA at East Coast Antibody HubXChange. Jane will be presenting beautiful data about creating, interrogating, and capturing incredible antibody diversity for superior biologics drug discovery.

Metric
Company Name	Ablexis	HBM Holdings Limited
Symbol		2.14K
MSH ID	COM:ABLEXIS	COM:HARBOURBIOMED
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	CN
Stage	Series A	Series C
Employee Count		177
Website	ablexis.com	harbourbiomed.com
LinkedIn	ablexis
Founders

Metric
Market Cap		131.38M
Enterprise Value
Monthly Web Traffic		603
Web Traffic Growth		-0.14
Valuation
Raised Capital	12M	102.80M

Metric
Revenue		89.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit		87.47M
EBITDA		26.65M
Operating Income		21.83M
Net Income		22.80M
EPS		0.03
Diluted EPS		0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		1.00
Operating Profit Margin		0.28
EBITDA Margin		0.30
Net Profit Margin		0.31
Return on Equity		0.21
Return on Assets		0.10
Return on Capital Employed		0.13

ABLE

COM:ABLEXIS

Ablexis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-1.03
P/B Ratio		1.52
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.57
EV Multiple		12.92

Metric
Days Sales Outstanding
Days Payables Outstanding		61.85K
Days Inventory Outstanding		4.29K
Operating Cycle		4.34K
Cash Conversion Cycle		-536.87
Asset Turnover		0.39

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt		0.32
Operating Cash Flow/Sales		0.29
Free Cash Flow Yield		-0.76

Metric
Cash & Equivalents		140.32M
Accounts Receivable
Inventory		1
Goodwill
Debt to Capitalization		0.45
Debt to Assets		0.39
Current Ratio		2.79
Quick Ratio		3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue		3.32
SG&A to Revenue		0.25